Targan has secured $35 million of Series C equity financing. The financing was co-led by Mountain Group Partners and NovaQuest Capital Management.

TARGAN is a biotechnology systems company poised to transform animal protein production industries.

“From its conception, TARGAN’s purpose has been to address the growing global demand for a healthier, more sustainable food supply through the development and application of novel technologies,” said Ramin Karimpour, CEO of TARGAN. “We are delighted that our great progress has led to NovaQuest joining our existing investors in this series. With this round, we will launch our targeted, individual vaccination and gender sorting technologies for poultry.”

Wyrick Robbins Yates & Ponton LLP acted as legal counsel to NovaQuest. Baker, Donelson, Bearman, Caldwell & Berkowitz served as legal counsel to Mountain Group.